Topic 3 — PRAME: A High-Value Melanoma Target

“Advancing Melanoma Care: Early Identification, Timely Action, and Next-Generation Therapy,” is an educational video series focusing on earlier identification of advanced melanoma, routine HLA-A*02:01 testing, and timely referral to IMA203 (anzu-cel) trial sites. In Topic 3, “PRAME: A High-Value Melanoma Target,” Alison Betof, MD, PhD, FASCO—Director, Melanoma Program, Mark and Mary Stevens Endowed Scholar in Melanoma, and Director, Solid Tumor Cellular Therapy at Stanford University School of Medicine—highlights how PRAME is one of the most consistently expressed, tumor- selective intracellular antigens in melanoma — and a cornerstone of next-generation cell therapy development. Topics in this brief educational video include PRAME as an important target in melanoma, how frequently PRAME expressed in melanoma and other cancers, and how PRAME and HLA work together to determine treatment eligibility. In addition, watch the third segment of the series to gain better understanding as to why HLA-A*02:01 is critical for PRAME-targeted therapies.